It was initially observed that patients with KRAS mutant CRC do not respond to epidermal growth factor rector (EGFR)-targeted agents such as the monoclonal antibodies cetuximab and panitumumab [4, 5]. This evidence concerns the gene KRAS and colorectal carcinoma.